March 18, 2021
GREAT NEWS FOR EXCELLIRATE CANADA: EXPANDING CELL-BASED IMMUNOTHERAPY RESEARCH ACCELERATION FOR TRANSLATION AND EVALUATION PROGRAM, CO-LEAD BY ANNETTE HAY
The Canadian Cancer Trials Group (CCTG) and Queen’s researcher Annette Hay (Medicine) and Jonathan Bramson, of McMaster University, have received CFI support of more than $5 million for their project to develop a national cellular therapy translational research platform, the first of its kind globally. ExCELLirate Canada: Expanding CELL-based Immunotherapy Research Acceleration for Translation and Evaluation is a collaboration between Queen’s, McMaster University, University of Calgary, University of Ottawa, Université de Montréal, and Canadian Blood Services. CFI funds will support research activities from novel cell therapy development to point-of-care cell manufacturing and multi-centre clinical trial testing for cancer treatment. This project aims to develop cell therapies as safe and viable treatment options through identifying biological mechanisms affecting safety and designing cost-effective methods for the harvest, expansion, manipulation, purification, and delivery of the cells.
Read the following articles to know more: